imatinib
Sign in to saveImatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c-KIT, FLT3, and PDGFR-β. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome–positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelo
Key facts
- Drug.verifiedrevid
- 459451238
- Drug.image
- Imatinib2DACS.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- File:Imatinib structure.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 280
- Drug.alt2
- Ball-and-stick model of the imatinib molecule
- Drug.pronounce
- ih-MAT-ih-nib
- Drug.tradename
- Gleevec, Glivec, others
- Drug.MedlinePlus
- a606018
- Drug.DailyMedID
- Imatinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.class
- Tyrosine kinase inhibitor
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EA01
- Drug.legal_AU
- S4
via Wikipedia infobox
Article
28 sectionsContents
- Medical uses
- Chronic myelogenous leukemia
- Gastrointestinal stromal tumors
- Dermatofibrosarcoma protuberans (DFSP)
- Other
- Contraindications and cautions
- Side effects
- Cardiotoxicity
- Childhood growth inhibition
- Pigmentation changes
- Hepatotoxicity
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Other pathways affected
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Society and culture
- Economics
- Controversies
- Patent litigation in India
- Research
- Etymology
- References
- External links
{{infobox drug | verifiedrevid = 459451238 | image = Imatinib2DACS.svg | image_class = skin-invert-image | width = 250 | alt = | image2 = File:Imatinib structure.png | image_class2 = bg-transparent | width2 = 280 | alt2 = Ball-and-stick model of the imatinib molecule | caption = | pronounce = ih-MAT-ih-nib | tradename = Gleevec, Glivec, others | Drugs.com = | MedlinePlus = a606018 | DailyMedID = Imatinib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Tyrosine kinase inhibitor | ATC_prefix = L01 | ATC_suffix = EA01 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status =
| bioavailability = 98% | protein_bound = 95% | metabolism = Liver (mainly CYP3A4-mediated) | metabolites = | onset = | elimination_half-life = 18 h (imatinib)40 h (active metabolite) | duration_of_action = | excretion = Fecal (68%) and kidney (13%)
Gallery (8)
Connections
Categories
3-Pyridyl compounds4-Methylpiperazin-1-yl compoundsAminopyrimidinesBenzanilidesBenzylpiperazinesCancer treatmentsCYP3A4 inhibitorsDrugs developed by NovartisDrugs with non-standard legal statusECHA InfoCard ID from WikidataNon-receptor tyrosine kinase inhibitorsOrphan drugsWorld Health Organization essential medicines